India’s Sun Pharma Claims Taro’s Proposed Sale Of Irish Plant Not Transparent
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - The spurned suitor of Taro Pharma has accused the Israel-based firm of favoring family in the proposed sale of an Irish manufacturing plant at Roscrea, Ireland, in an increasingly bitter battle following Taro's termination of a merger agreement earlier this month
You may also be interested in...
Sun Pharma Extends Offer For Taro Shares In Ongoing Rocky Affair
MUMBAI - Sun Pharmaceutical has extended the tender offer for purchase of all outstanding ordinary shares of Israeli drug maker Taro Pharmaceuticals until September 2
Sun Pharma Extends Offer For Taro Shares In Ongoing Rocky Affair
MUMBAI - Sun Pharmaceutical has extended the tender offer for purchase of all outstanding ordinary shares of Israeli drug maker Taro Pharmaceuticals until September 2
PharmAsia News Notable Notes: Citigroup Reiterates Buy On India’s Sun Pharma
NEW DELHI - Citigroup Global Markets reiterated its buy on Sun Pharma, India's largest drug company by market capitalization, saying a recent price dip related to a disputed merger attempt with Israel's Taro Pharma offers a "window of opportunity.